NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a phase I trial with an oral capsule form of ZIO-101, the Company’s proprietary small molecule organic arsenic. The injectable (IV) form of ZIO-101 is currently in three phase II studies including advanced myeloma, liver cancer, and hematological malignancies. The phase I study of oral ZIO-101 will include patients with advanced solid tumors and will evaluate safety and pharmacokinetics. Starting dose will be 300 mg two days per week for three weeks followed by a one week break.
